- Home
- LI vs RPRX Comparison
LI vs RPRX Comparison
Compare LI & RPRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | LI | RPRX |
|---|---|---|
| Founded | 2015 | 1996 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Auto Manufacturing | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 16.8B | 19.5B |
| IPO Year | N/A | 2020 |
Fundamental Metrics
Financial Performance| Metric | LI | RPRX |
|---|---|---|
| Price | $18.43 | $48.54 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 10 | 4 |
| Target Price | $19.66 | ★ $47.75 |
| AVG Volume (30 Days) | ★ 3.3M | 2.9M |
| Earning Date | 03-12-2026 | 05-07-2026 |
| Dividend Yield | N/A | ★ 1.96% |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 1.78 |
| Revenue | N/A | ★ $2,378,193,000.00 |
| Revenue This Year | $24.20 | $38.30 |
| Revenue Next Year | $22.91 | $4.80 |
| P/E Ratio | $29.50 | ★ $26.94 |
| Revenue Growth | N/A | ★ 5.06 |
| 52 Week Low | $15.71 | $29.66 |
| 52 Week High | $32.03 | $47.98 |
Technical Indicators
Market Signals| Indicator | LI | RPRX |
|---|---|---|
| Relative Strength Index (RSI) | 57.53 | 69.65 |
| Support Level | $16.30 | $35.32 |
| Resistance Level | $18.92 | N/A |
| Average True Range (ATR) | 0.45 | 0.89 |
| MACD | 0.07 | 0.12 |
| Stochastic Oscillator | 74.20 | 93.16 |
Price Performance
Historical ComparisonAbout LI Li Auto Inc.
Li Auto is a leading Chinese NEV manufacturer that designs, develops, manufactures, and sells premium smart NEVs. The company started volume production of its first model Li One in November 2019. The model is a six-seater, large, premium plug-in electric SUV equipped with a range extension system and advanced smart vehicle solutions. It sold over 500,000 NEVs in 2024, accounting for about 4% of China's passenger new energy vehicle market. Beyond Li One, the company expands its product line, including both BEVs and PHEVs, to target a broader consumer base.
About RPRX Royalty Pharma plc
Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.